Aardvark Therapeutics, Inc. AARD 深 沪
等待开盘 03-26 09:30:00 美东时间
3.54
-0.230
-6.10%
华盛通- 最 高3.88
- 今 开3.88
- 成交量 24.93万股
- 最 低 3.52
- 昨 收 3.77
- 总市值 7707.74万
- 52周最高 17.94
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 3.52
- 委 比 -33.61%
- 总股本 2177.33万
- 历史最高 19.58
- 量 比 0.73
- 振 幅 9.55%
- 历史最低 3.52
- 每 手 1
- 风险率 2.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $9 Price Target
BTIG analyst Jeet Mukherjee reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Buy and maintains $9 price target.
03-24 18:59
Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.91) by 11.09 percent. This is a 62.5 percent increase over losses of $(2.16) per share
03-24 04:06
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Azitra (AMEX:AZTR) stock rose 52.6% to $0.27 during Friday's regular s...
03-21 01:06
What's Going On With Aardvark Therapeutics Stock On Wednesday?
Aardvark Therapeutics pauses Phase 3 HERO trial after cardiac safety observations, sending shares down nearly 61%.
03-04 21:54
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Market-Moving News for March 2nd
HKD: 51% | AMTD Digital shares are trading higher after the company reported a year-over-year increase in FY25 revenue results. AARD: -56% | Aardvark Therapeutics shares are trading lower
03-02 20:41
Why Is Aardvark Therapeutics Stock Sinking Monday?
AARD shares down on pause of Phase 3 HERO trial for Prader-Willi Syndrome due to safety concerns, may impact study outcomes and future plans.
03-02 20:02
Aardvark Therapeutics Voluntarily Pauses Phase 3 HERO Trial Of ARD-101 In Prader-Willi Syndrome After Reversible Cardiac Findings At Supratherapeutic Doses; Delays Expected Q3 2026 Topline Data
Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of
02-28 05:06
